gvtcx

Framework Agreement For Producer Cell Line For GMP Viral Vector Packaging

NHS Blood & Transplant Published 3 Jun 2020 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£100,000
Statusactive
Category (CPV) 33141000
RegionSouth West
Deadline5 Jul 2020
Contract start1 May 2021
Contract end30 Sept 2023
Procedureopen
SME suitableYes
OCIDocds-b5fd17-8781e3bf-98bb-489d-8e81-af61c3421f67

description

NHSBT's Clinical Biotechnology Centre has a requirement for specifying the user requirement for HEK293-derived production cell line for the GMP-production of viral vectors and other recombinant proteins. The CBC has an MHRA licence for the manufacture of investigational medicinal gene therapy and recombinant protein products for use in clinical trials. In order to manufacture GMP-grade viral vectors and recombinant proteins for clinical trials, a GMP-qualified producer cell line is required

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
3 Jun 2020 Tender (tender) · ddb492e1-255a-4c98-85fd-647c041c5232-362031

more from NHS Blood & Transplant

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.